featured
Outcomes of 10-Day Decitabine vs 3 + 7 Chemotherapy Followed by Allografting in Older Patients With AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
Lancet Haematol 2023 Nov 01;10(11)e879-e889, M Lübbert, PW Wijermans, M Kicinski, S Chantepie, WJFM Van der Velden, R Noppeney, L Griškevičius, A Neubauer, M Crysandt, R Vrhovac, M Luppi, S Fuhrmann, E Audisio, A Candoni, O Legrand, R Foà, G Gaidano, D van Lammeren-Venema, EFM Posthuma, M Hoogendoorn, A Giraut, M Stevens-Kroef, JH Jansen, AO de Graaf, F Efficace, E Ammatuna, JP Vilque, R Wäsch, H Becker, N Blijlevens, U Dührsen, F Baron, S Suciu, S Amadori, A Venditti, G HulsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.